Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Collaboration expense, net

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

CRISPR Therapeutics

CRISPR Therapeutics AG is a gene editing company, which engages in the development of transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. Its CRISPR/Cas9 platform is a gene editing technology that allows for precise, directed changes to genomic DNA. The firm offers a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine, and rare diseases. The company was founded by Rodger Novak, Emmanuelle Charpentier, Shaun Patrick Foy, Matthew Porteus, Daniel Anderson, Chad Cowan and Craig Mellow on October 31, 2013 and is headquartered in Zug, Switzerland.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

CRISPR Therapeutics AG is a gene editing company, which engages in the development of transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. Its CRISPR/Cas9 platform is a gene editing technology that allows for precise, directed changes to genomic DNA. The firm offers a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine, and rare diseases. The company was founded by Rodger Novak, Emmanuelle Charpentier, Shaun Patrick Foy, Matthew Porteus, Daniel Anderson, Chad Cowan, and Craig Mellow on October 31, 2013 and is headquartered in Zug, Switzerland.

CRISPR Therapeutics AG (NASDAQ:CRSP ) Jefferies London Healthcare Conference November 20, 2024 11:00 AM ET Company Participants Samarth Kulkarni - Chief Executive Officer and Chairman Conference Call Participants Maury Raycroft - Jefferies Maury Raycroft Hi, everyone. My name is Maury Raycroft, I'm one of the biotech analysts at Jeffreys.

CRISPR Therapeutics AG (CRSP) Jefferies London Healthcare Conference (Transcript)

The decline in CRSP's share price could be due to the beating the drug/biotech sector has been taking in the past couple of months, resulting from pipeline setbacks and guidance cuts.

CRISPR Therapeutics Stock Falls 7% in Two Weeks: Time to Hold or Sell?

Iovance Biotherapeutics

2 Top Biotech Stocks to Buy Now and Hold For 5 Years or More

CRISPR Therapeutics AG (NASDAQ:CRSP ) Guggenheim Inaugural Healthcare Innovation Conference November 12, 2024 2:00 PM ET Company Participants Samarth Kulkarni - CEO and Chairman Conference Call Participants Debjit Chattopadhyay - Guggenheim Partners Debjit Chattopadhyay Good afternoon and thank you for joining us at Guggenheim's Inaugural Healthcare Innovations Conference. I am Debjit and one of the therapeutic analysts here.

CRISPR Therapeutics AG (CRSP) Guggenheim Inaugural Healthcare Innovation Conference (Transcript)

Where Will CRISPR Therapeutics Be in 3 Years?

ZUG, Switzerland and BOSTON, Nov. 14, 2024 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today announced that Samarth Kulkarni, Ph.D., Chief Executive Officer and Chairman of CRISPR Therapeutics, will present at the Jefferies London Healthcare Conference on Wednesday, November 20, 2024, at 4:00 p.m. GMT.

CRISPR Therapeutics to Present at the Jefferies London Healthcare Conference

Archer Aviation

IonQ

These three emerging technology leaders are pioneering quantum computing, gene editing, and electric aviation.

3 Unstoppable Growth Stocks I'm Loading $25,000 Each Into by 2029

CRISPR Therapeutics' Casgevy, the first CRISPR/Cas9 gene editing therapy, shows promising results in treating Sickle Cell Disease and beta thalassemia but faces challenges in patient adoption and cost. Despite no Q3 revenue from Casgevy, CRISPR maintains a strong cash position and continues to advance its diverse pipeline, including CAR-T and in-vivo therapies. Vertex's partnership and investment highlight Casgevy's potential, but long-term success hinges on improving treatment processes and securing further drug approvals.

Crispr Therapeutics Q3 Earnings: No Casgevy Revenue, But Plenty Of Optimism

The mean of analysts' price targets for CRISPR Therapeutics (CRSP) points to a 62.8% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Wall Street Analysts See a 62.75% Upside in CRISPR Therapeutics (CRSP): Can the Stock Really Move This High?

CRISPR Therapeutics reports mixed third-quarter results. The commercial launch of the first CRISPR-based gene therapy, Casgevy, is progressing well.

CRSP's Q3 Loss Narrower Than Expected, Sales Miss Estimates

CRISPR Therapeutics AG (CRSP) came out with a quarterly loss of $1.01 per share versus the Zacks Consensus Estimate of a loss of $1.33. This compares to loss of $1.41 per share a year ago.

CRISPR Therapeutics AG (CRSP) Reports Q3 Loss, Lags Revenue Estimates

-CASGEVY™ approved for the treatment of patients 12 years of age and older with sickle cell disease (SCD) and transfusion-dependent beta thalassemia (TDT) in Switzerland and Canada-

CRISPR Therapeutics Provides Business Update and Reports Third Quarter 2024 Financial Results

Rocket Lab USA

Serve Robotics Inc

These pioneering companies are transforming delivery, medicine, and space access--potentially creating massive opportunities for early investors.

3 Companies Building Tomorrow's Game-Changing Technologies

CRISPR Therapeutics AG (CRSP) is looking like an interesting pick from a technical perspective, as the company reached a key level of support. Recently, CRSP crossed above the 20-day moving average, suggesting a short-term bullish trend.

CRISPR Therapeutics AG (CRSP) Just Overtook the 20-Day Moving Average

After reaching an important support level, CRISPR Therapeutics AG (CRSP) could be a good stock pick from a technical perspective. CRSP surpassed resistance at the 50-day moving average, suggesting a short-term bullish trend.

CRISPR Therapeutics AG (CRSP) Recently Broke Out Above the 50-Day Moving Average

It won't be able to be profitable without hitting its targets for both of these figures.

Thinking of Buying CRISPR Therapeutics Stock? Watch These 2 Key Numbers

Applied Blockchain Inc

Joby Aviation

Intuitive Machines Inc

Intellia Therapeutics

Navitas Semiconductor Corp

Prime Medicine Inc

SoundHound AI Inc

Virgin Galactic

These 12 innovative companies could deliver exponential returns over the next quarter century.

12 High-Growth Stocks That Could Deliver Parabolic Returns

On CRSP's third-quarter 2024 earnings call, investors will likely focus on the sales numbers of its recently approved gene therapy, Casgevy.

CRISPR Therapeutics to Report Q3 Earnings: Is a Beat in Store?

Crispr Therapeutics, a leader in CRISPR/Cas9 biotechnology, recently received FDA and EMA approval for Casgevy, the first CRISPR/Cas9-based treatment for TDT and SCD. The partnership with Vertex Pharmaceuticals has provided significant financial support, experienced leadership, and validation, positioning Crispr for long-term success in the gene-editing space. Crispr's shares are currently undervalued, offering a strong buy opportunity below $50, with incoming revenue from Casgevy and a promising drug pipeline.

Crispr Therapeutics: Poised For A Major Turnaround

This company might be worth far more than many realize.

The Ultimate Biotech Stock to Buy With $50 Right Now

The latest trading day saw CRISPR Therapeutics AG (CRSP) settling at $47.36, representing a -1.23% change from its previous close.

CRISPR Therapeutics AG (CRSP) Registers a Bigger Fall Than the Market: Important Facts to Note

Blueprint Medicines

Exelixis

Amicus Therapeutics

Verona Pharma

New drug approvals and strong pipeline progress are likely to help maintain the momentum for the Zacks Biomedical and Genetics industry. A strong portfolio and solid pipeline progress position EXEL, BPMC, CRSP, FOLD and VRNA well in this volatile sector.

5 Biotech Stocks Likely to Outperform as Industry Prospects Look Bright

In the most recent trading session, CRISPR Therapeutics AG (CRSP) closed at $48.51, indicating a -0.84% shift from the previous trading day.

CRISPR Therapeutics AG (CRSP) Falls More Steeply Than Broader Market: What Investors Need to Know

The average of price targets set by Wall Street analysts indicates a potential upside of 67.5% in CRISPR Therapeutics (CRSP). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Wall Street Analysts See a 67.54% Upside in CRISPR Therapeutics (CRSP): Can the Stock Really Move This High?

Axsome Therapeutics

Pfizer

Yes, bargains can still be found in the stock market.

News for CRISPR Therapeutics Stock (CRSP)